The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

Turan et al., The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328

Feb 2022

Source PDF All Studies Meta AnalysisMeta

Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to substantial confounding by time because the patients in each group are from different time periods with an overall period of 10 months including the beginning of the pandemic, resulting in significant differences in variants encountered and SOC. Propensity for hospital admission may also have changed significantly. This study is excluded in meta analysis: substantial confounding by time likely due to separation of groups in different time periods over an extended period of time.

Important missing comments or errors? Let us know.

risk of hospitalization, 79.4% lower, RR 0.21, p = 0.001, treatment 4 of 123 (3.3%), control 18 of 114 (15.8%), NNT 8.0.

recovery time, 11.0% higher, relative time 1.11, p = 0.51, treatment 123, control 114.

time to viral-, 21.6% lower, relative time 0.78, p < 0.001, treatment 123, control 114.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Turan et al., 1 Feb 2022, retrospective, Turkey, peer-reviewed, mean age 33.4, 10 authors, study period 11 March, 2020 - 1 January, 2021, this trial compares with another treatment - results may be better when compared to placebo.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

Derya Bayırlı Turan, Mehtap Menteş, Yıldıran Özel, Kıvanç Şerefhanoğlu, Burcu Aydoğan, Neşe İbil, Füsun Güneşdoğdu, Hijran Mammadova Orucova, Cüneyt Saltürk, Hakan Çelik

The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2022.102328

Objectives: Comparative data on hydroxychloroquine and favipiravir, commonly used agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited. In this study, it was aimed to compare treatment outcomes in healthcare workers with COVID-19 who were prospectively followed by the occupational health and safety unit. Methods: A total of 237 healthcare-workers, diagnosed as mild or moderate COVID-19 between March 11, 2020 and January 1, 2021, were given hydroxychloroquine (n = 114) or favipiravir (n = 123). Clinical and laboratory findings were evaluated. Results: The mean age of the patients was 33.4 §11.5 years. The mean time to negative PCR was found to be significantly shorter in patients receiving favipiravir compared to the hydroxychloroquine group (10.9 vs. 13.9 days; p < 0.001). The rate of hospitalization in the hydroxychloroquine group was significantly higher than favipiravir group (15.8% vs. 3.3%). In terms of side effects; the frequency of diarrhea in patients receiving hydroxychloroquine was significantly higher than that in the favipiravir group (31.6% vs. 6.5%; p < 0.001). Conclusions: Favipiravir and hydroxychloroquine were similar in terms of improvement of clinical symptoms of healthcare workers with mild or moderate COVID-19 infection, but favipiravir was significantly more effective in reducing viral load and hospitalization rates. Furthermore, favipiravir caused significantly less side-effects than hydroxychloroquine.

References

Agrawal, Raju, Udwadia, Favipiravir: a new and emerging antiviral option in COVID-19, Med J Armed Forces India, doi:10.1016/j.mjafi.2020.08.004

Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007

Cap, Bilge, Isik, The effect of favipiravir on QTcinterval in patients hospitalized with coronavirus disease

Coomes, Haghbayan, Favipiravir, an antiviralfor COVID-19?, J Antimicrob Chemother, doi:10.1093/jac/dkaa171

Costanzo, Giglio, Roviello, SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus, Curr Med Chem, doi:10.2174/0929867327666200416131117

Covid-, This finding indicates that if SARS-CoV-2 PCR neg-284 ativity is expected, lost work time can be reduced. 285 The present study had some limitations. In order to make 286 a direct comparison of hydroxychloroquine and favipiravir 287 and to avoid bias, patients who received these agents in com-288 bination with other drugs

Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1128/AAC.01897-20

Elavarasi, Prasad, Seth, Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis, J Gen Intern Med, doi:10.1007/s11606-020-06146-w

Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B, doi:10.2183/pjab.93.027

Ghasemnejad-Berenji, Pashapour, Favipiravir and COVID-19: a simplified summary, Drug Res, doi:10.1055/a-1296-7935

Hernandez, Roman, Pasupuleti, Barboza, White, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann Intern Med, doi:10.7326/M20-2496

Hu, Guo, Zhou, Shi, Characteristics of SARS-CoV-2 315 and COVID-19, Nat Rev Microbiol, doi:10.1038/s41579-020-00459-7

Ib Añez, Martínez, Valenzuela, Silva, Valenzuela, Hydroxychloroquineand chloroquine in COVID-19: should they be used as standard therapy?, Clin Rheumatol, doi:10.1007/s10067-020-05202-4

Izci-Cetinkaya, Karag€ Oz, Yildiz, Comparison of liver safety of favipiravir and hydroxychloroquine in COVID-19 treatment, Klimik Derg, doi:10.5152/kd.2020.49

Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.069

Kaptein, Jacobs, Langendries, Favipiravir at highdoses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2014441117

Mehta, Mazer-Amirshahi, Alkindi, Pourmand, Pharmacotherapy in COVID-19; A narrative review for 319 emergency providers, Am J Emerg Med, doi:10.1016/j.ajem.2020.04.035

Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and metaanalysis, Virol J, doi:10.1186/s12985-020-01412-z

Sinha, Balayla, Hydroxychloroquine and COVID-19, Postgrad Med J, doi:10.1136/postgradmedj-2020-137785

Therefore, favipiravir is thought to be a useful agent in the 305 treatment of mild or moderate COVID-19 infection

Therefore, lost work time was 276 similar in patients who received hydroxychloroquine or favi-277 piravir

Yousefi, Valizadeh, Ghaffari, Vahedi, Karbalaei et al., A global treatments for coronaviruses including COVID-19, J Cell Physiol, doi:10.1002/jcp.29785

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0